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(M.J. Saraiva), ralmeida@ibmc.up.pt (M.R. Almeida).Several natural polyphenols with potent inhibitory effects on amyloid ﬁbril formation have been
reported. Herein, we studied modulation of transthyretin (TTR) ﬁbrillogenesis by selected polyphe-
nols. We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and
stabilize the TTR tetramer. However, while NDGA slightly reduced TTR aggregation, curcumin
strongly suppressed TTR amyloid ﬁbril formation by generating small ‘‘off-pathway’’ oligomers
and EGCG maintained most of the protein in a non-aggregated soluble form. This indicates alterna-
tive mechanisms of action supported by the occurrence of different non-toxic intermediates. More-
over, EGCG and curcumin efﬁciently disaggregated pre-formed TTR amyloid ﬁbrils. Our studies,
together with the safe toxicological proﬁle of these phytochemicals may guide a novel pharmaco-
therapy for TTR-related amyloidosis targeting different steps in ﬁbrillogenesis.
Structured summary of protein interactions:
TTR binds to TTR by comigration in gel electrophoresis (View interaction)
TTR binds to TTR by dynamic light scattering (View interaction)
TTR binds to TTR by electron microscopy (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction monomer polypeptide chain induces subtle structural alterationsTransthyretin (TTR) variants are related with different forms of
hereditary amyloidoses and in particular with Familial Amyloidotic
Polyneuropathy (FAP). Among more than one hundred single ami-
no acid variants reported, the most frequent one is TTR V30M, in
which valine (V) 30 is substituted by a methionine (M) [1]. This
variant presents high tendency to aggregate and to deposit in par-
ticular in peripheral nerves, but also in heart, eye and in fewer
cases, carpal tunnel or leptomeninges revealing clinical and molec-
ular heterogeneity [2]. TTR L55P, a variant with a substitution of a
proline for leucine, is highly amyloidogenic and is associated with
the most aggressive form of the disease [3]. Likewise, TTR Y78F is a
very aggregate-prone mutant, namely under physiological condi-
tions [4], while TTR T119M, with a substitution of methionine for
threonine, is a non-amyloidogenic and non-pathogenic TTR variant
with protective properties [5].
The TTRmolecule is a tetramer of identical subunits of 127 amino
acid residues each. The occurrence of amino acid substitutions in thechemical Societies. Published by E
Molecular, IBMC – Instituto
legre, 823, 4150-180 Porto,
reira), mjsaraiv@ibmc.up.ptthat decrease the stability of the tetramer and increase the amyloi-
dogenic potential of the protein. Thus, it is widely accepted that
molecular mechanisms underlying TTR amyloid ﬁbril formation in-
volve destabilization of the TTR tetramer that dissociates into non-
native monomers with low conformational stability and aggregates
to form amyloid ﬁbrils [6,7].
Considering this mechanism, several small compounds have
been suggested for TTR amyloidosis therapy, acting as TTR stabiliz-
ers, impairing amyloid ﬁbril formation or disrupting TTR ﬁbrils.
Among those, are non-steroidal anti-inﬂammatory drugs (NSAIDs)
and derivatives or natural compounds [8,9]. However some of the
previously suggested compounds present low binding afﬁnity or
low selectivity of binding to TTR ex vivo and, in some cases, severe
adverse side effects associated with their administration in vivo
[10–12]. Recently, our group reported that ()-epigallocatechin
gallate (EGCG), the most abundant catechin in green tea, inhibits
TTR aggregation in vitro [13] raising the possibility of using this
polyphenol or analogs to treat FAP.
Curcumin, nordihydroguaiaretic acid (NDGA), rosmarinic acid,
caffeic acid and scyllo-inositol are natural occurring polyphenols
presenting structural similarities with thyroxine (T4), a physiologic
TTR ligand. Most of them have been suggested for the prevention
and treatment of neurodegenerative disorders such as Alzheimer’slsevier B.V. All rights reserved.
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ruption of pre-existing ﬁbrils of amyloid-b (Ab) or a-synuclein
(aS) [14,15]. In the present work, we evaluated the ability of these
phytochemicals to bind TTR and modulate different steps of the
process of TTR amyloid ﬁbril formation, in comparison with EGCG.
2. Materials and methods
2.1. Reagents
()-Epigallocatechin gallate (EGCG) and curcumin were pur-
chased from Cayman Chemicals (Ann Arbor, MI, USA) and nord-
ihydroguaiaretic acid (NDGA), rosmarinic acid and caffeic acid
from Sigma–Aldrich (St. Louis, MO, USA).
2.2. Samples
Whole blood from ﬁve heterozygotic carriers of TTR V30M and
from ﬁve control individuals was collected in the presence of EDTA
and centrifuged for plasma separation. All donors gave informed
consent.
Recombinant wild-type TTR (TTR WT) and TTR variants, namely
TTR V30M, TTR L55P and TTR Y78F, were produced in a bacterial
expression system and puriﬁed as previously described [12].
2.3. T4 competition assays
Displacement of T4 from TTR, either from plasma or recombi-
nant, was assayed qualitatively by incubation of whole plasma
(5 ll) or recombinant protein (10 lg) with [125I]T4 (speciﬁc radio-
activity 1250 lCi/lg; Perkin–Elmer, MA, USA) in the presence of
different phytochemicals (10 molar excess relative to TTR tetra-
mer) solubilized in DMSO. Subsequently, proteins were separated
by PAGE, revealed by phosphor imaging and quantiﬁed using the
ImageQuant program version 5.1. [12]. Competition of polyphenols
with T4 for the binding to TTR was quantitatively assayed by gel ﬁl-
tration as previously described [12]. Brieﬂy, TTR WT (30 nM) in
Tris/NaCl/EDTA buffer was incubated with a trace amount of
[125I]T4 and with increasing concentrations (0–10 lM) of competi-
tors. [125I]T4 bound to TTR was separated from free T4 through gel
ﬁltration column. All samples were run in duplicate and the data
was analyzed using GraphPad Prism 2.0.
2.4. Isoelectric focusing (IEF) in semi-denaturing conditions
Thirty microliters of human plasma from ﬁve TTR V30M hetero-
zygotic carriers and ﬁve control individuals were incubated in the
presence of the phytochemicals (5 ll of a 10 mM solution) at 37 C
for 1 h. The samples were subjected to PAGE, and the TTR gel band
was excised and applied to a semi-denaturing (4 M urea) pH 4–6.5
gradient IEF gel [12]. Proteins were stained with Coomassie Blue.
The gels were scanned and subjected to densitometry analysis
using the ImageQuant program.
2.5. Dynamic light scattering (DLS) and transmission electron
microscopy (TEM)
A solution of TTR Y78F (2 mg/ml) in PBS with or without 10
molar excess of different polyphenols was ﬁltered through 0.2 lm
Anotop syringe ﬁlters (Whatman, England) and incubated at 37 C
for 4, 6, 12 and 16 days. DLS measurements were performed at
25 C in a Malvern Zetasizer Nano ZS (Malvern, Worcestershire,
UK). Each sample was measured tree times; average distributions
are presented.
Aliquots from the samples studied by DLS were also analyzed by
TEM as previously reported [13,16]. Sample aliquots (5 ll) wereadsorbed to carbon-coated collodion ﬁlm supported on 200-mesh
copper grids. The grids were negatively stained with 1% uranyl ace-
tate and visualized with a Zeiss microscope at 60 kV.
2.6. Cell culture assays
To test the different polyphenols as TTR aggregation inhibitors
we used a rat Schwannoma (RN22) (American Type Cell Collection)
cell line stably transfected with TTR L55P cDNA [16]. Cells were
grown till 80% cell conﬂuence with the compounds at 1 lM con-
centration in cell medium (5 days). Then, cells were incubated
for further 24 h still in the presence of compounds but in serum-
free media. TTR in the medium was quantiﬁed by ELISA, and equal
amounts of TTR (500 ng) were doted onto a 0.2 lm pore cellulose
acetate membrane – dot-blot ﬁlter assay. TTR aggregates retained
in the membrane were immunodetected using rabbit anti-human
TTR (DAKO) (1:500) followed by anti-rabbit HRP antibody
(1:1500) and ECL visualization (GE Healthcare). Dot blots were
quantiﬁed using the ImageQuant program. Experiments were re-
peated at least three times in duplicate. All values are expressed
as means ± S.D. Comparison between groups was made using the
Student’s t-test, a P value of less than 0.05 was considered statisti-
cally signiﬁcant.
2.7. Cell toxicity assays
Rat Schwannoma cells (RN22) were propagated and maintained
as described previously [16]. Brieﬂy, 80% conﬂuent cells in Dul-
becco’s minimal essential medium with 1% fetal bovine serum
were exposed for 24 h to 2 lM of TTR Y78F oligomers. These olig-
omers were obtained by incubation of soluble TTR Y78F either in
the absence or presence of a 10 molar excess of EGCG, curcumin
or NDGA at 37 C for 6 days. Then, cells were trypsinized and cell
lysates were used for determination of caspase-3 activation with
the CaspACE ﬂuorimetric 96-well plate assay system (Sigma). Pro-
tein concentration in lysates was determined with the Bio-Rad pro-
tein assay kit.
2.8. Disruption of TTR ﬁbrils
To study the effect of the different polyphenols on TTR ﬁbrils
disruption, we used TTR pre-formed ﬁbrils prepared by incubation
of a ﬁltered (0.2 lm ﬁlters) solution of TTR L55P (2 mg/ml in PBS)
for 15 days at 37 C. Subsequently, the samples were incubated
either in the absence (control) or presence of a 10 molar excess
of the polyphenols for 4 days at 37 C. The disruption effect was
evaluated by TEM and DLS, as described above.
3. Results
3.1. Competition for T4 binding
To determine the ability of polyphenols to compete with T4 for
the binding to TTR the compounds were incubated with isolated
TTR, either recombinant WT (data not shown) or V30M (Fig. 1A),
and [125I]T4 and the samples were analyzed by PAGE. Similar
ex vivo assays were performed with TTR in whole plasma from het-
erozygote TTR V30M carriers or control individuals (data not
shown). Samples incubated with curcumin and NDGA, presented
less intense TTR bands, indicating that both phytochemicals com-
peted with [125I]T4, being NDGA the strongest competitor.
Rosmarinic acid, caffeic acid and scyllo-inositol did not compete
with [125I]T4 for its binding to TTR.
The relative inhibition potency of binding, expressed as the ra-
tio of EC50 T4/EC50 competitor, was determined by competition of
Fig. 1. TTR binding and resistance to dissociation studies. (A) PAGE analysis of recombinant TTR V30M incubated with [125I] T4, in the absence or presence of the compounds.
(B) Curves of T4 displacement from TTRWT by polyphenols, obtained by gel ﬁltration assay. (C) IEF analysis of plasma TTR stability after treatment with polyphenols. Plasmas
from normal and TTR V30M heterozygotic carriers were treated with EGCG, curcumin, NDGA. Different molecular species visualized in the IEF gel after Coomassie Blue
staining are indicated. These gels are representative of others run in parallel. (D) The histogram shows TTR tetramer/total TTR bands ratio obtained after densitometry of IEF
gels corresponding to the analysis of 5 plasma samples (normal + V30M carriers) (⁄P 6 0.05; ⁄⁄P 6 0.01).
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sessed by gel ﬁltration. The displacement curves obtained (Fig. 1B)
demonstrate that NDGA is a more potent T4 competitor for the
binding to TTR than curcumin, with relative inhibition potencies
of 0.1 and 0.02, respectively. These results were consistent with
the in vitro and ex vivo data from the PAGE binding assay.
3.2. Effect of natural polyphenols on TTR tetramer dissociation
The effect of the natural polyphenols on TTR tetramer resistance
to dissociation was analyzed ex vivo by IEF under semi-denaturing
conditions. EGCG, formerly described as being a strong TTR tetra-
mer stabilizer, was used as Ref. [13]. In the absence of any com-
pound, plasma TTR presented a characteristic band pattern,
composed of monomer, an oxidized monomer and several lower
pI bands corresponding to different forms of tetramers. The ratio
tetramer/total TTR (tetramer + monomers) is normally higher
(0.63) for plasma from normal individuals than for the heterozyg-
otic TTR V30M carriers plasma (0.39) [12]. The results obtained for
plasma incubated with the different polyphenols showed that ros-
marinic acid, caffeic acid and scyllo-inositol do not stabilize TTR in
whole plasma (data not shown). On the contrary, curcumin incu-
bated samples displayed 25% increase of the tetramer/total TTR ra-
tio, in both normal and TTR V30M heterozygotic, whereas NDGA
had lower stabilizing effect (14%). EGCG, presented the strongest
stabilizing effect (30%), and also altered the migration of TTR tetra-
mers in the IEF gel as previously referred [13] (Fig. 1C and D).3.3. Effect of polyphenols on TTR aggregation in vitro
We next tested curcumin and NDGA for their effect on TTR Y78F
aggregation, by TEM and DLS analysis. This TTR variant forms ﬁ-
brils under physiologic conditions [4] and its aggregation pathway
has already been detailed by TEM [13]. In brief, soluble protein
evolves to oligomeric species and short twisted ﬁbrils within
2 days, forms large protein aggregates at 4 days, and after 6 days
of incubation the sample is mostly composed of ﬁbrils as shown
in Fig. 2A, control for 0, 4 and 6 days. TTR Y78F was incubated with
curcumin, NDGA and EGCG as reference inhibitor, and analyzed at
different time points, up to 16 days.
In accordance with previous results, EGCG powerfully impaired
pre-incubated TTR Y78F samples (Fig. 2A, EGCG for 4 and 6 days),
thus only soluble protein and small ‘‘off pathway’’ oligomers, but
no large aggregates or ﬁbrils, could be distinguished in the prepa-
rations for all time points analyzed. Similarly, in curcumin treated
samples, only small protein oligomers, but no larger protein aggre-
gates or ﬁbrils (at 4 and 6 days incubation), were detected
throughout the period investigated (16 days) (data not shown).
In contrast, NDGA pre-incubated samples displayed higher protein
aggregation in comparison with samples incubated with other
polyphenols, indicating that NDGA was not as effective as
curcumin or EGCG in preventing TTR Y78F aggregation (Fig. 2A,
NDGA at 4 and 6 days).
In parallel, the same samples were analyzed by DLS for addi-
tional characterization of the protein species formed. Initially,
Fig. 2. (A) TEM analysis of TTR Y78F aggregation, incubated at 37 C under stagnant conditions, in the absence (control) and presence of EGCG, curcumin or NDGA for 4 and
6 days. Scale bar = 200 nm. (B) DLS analysis of TTR Y78F aggregation for 0, 4 and 12 days in the absence (black line) and presence of EGCG (green line), curcumin (red line) and
NDGA (blue line).
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namic diameter (dH) (Fig. 2B) which is consistent with previous re-
port for the soluble TTR molecule [17]. After 4 days incubation, the
control sample (black line) exhibited a monodisperse particle pop-
ulation of dH around 2000 nm, corresponding to large protein
aggregates and ﬁbrils. Extended incubation, for 6, 12 and 16 days,
resulted in a homogenous population with dH around 4000 nm,
corresponding to TTR ﬁbrils and bulky aggregates. In the presence
of the different polyphenols, TTR Y78F aggregation followed di-
verse protein aggregation pathways. After 4 days, EGCG pre-incu-
bated samples (green line) displayed a major particle population
corresponding to soluble protein, indicating that this polyphenol
strongly inhibits TTR Y78F aggregation. This inhibitory effect was
maintained at 12 days and up to 16 days incubation. Curcumin
pre-treated samples (red line) presented a homogeneous popula-
tion of 80 nm dH, corresponding to small TTR aggregates, after
4 days incubation. This characteristic particle size homogeneity
was stably sustained during the period tested (16 days). Four days
after incubation, samples with NGDA (blue line) presented 2 main
particle populations corresponding to soluble protein and large
aggregates (dH  1000 nm). Although NDGA did not effectively im-
pair TTR ﬁbril formation, particle size (dH  1000 nm) was lower
than control (dH  4000 nm) after 12 days incubation period.
These results were consistent with those obtained from TEM.
Hence, curcumin is an efﬁcient inhibitor of TTR ﬁbril formation,
whereas NDGA is not. However, curcumin does not prevent ﬁbril
formation as efﬁciently as EGCG does and originates different
intermediates.
3.4. Effect of polyphenols on TTR aggregation in a cell culture system
The effect of curcumin and NDGA on TTR aggregation was also
investigated in a rat Schwannoma cell line transfected with TTR
L55P that secretes the TTR variant to the medium, where it aggre-
gates [16]. Conditioned mediumwas ﬁltered through cellulose ace-tate membrane and the retained aggregates are immunodetected
by anti-TTR antibody. In this assay, we compared the media ob-
tained by incubation of cells with curcumin, NDGA or EGCG to
the media of non-treated cells. Dot-blot of conditioned medium
obtained in the presence of curcumin (Fig. 3A) revealed almost
complete inhibition of TTR aggregation (90%). This effect was com-
parable to that of EGCG (Fig. 3B). NDGA reduced protein aggregate
formation but still its potency was approximately 4 lower than
that of curcumin.
3.5. Effect of polyphenols on TTR ﬁbril disruption
Comparison of crystallographic structure of TTR L55P with TTR
WT revealed key structural differences that might be representa-
tive of amyloid precursor species [18]. Thus, TTR L55P is an impor-
tant tool to study TTR ﬁbrillogenesis and amyloid formation
in vitro, under physiological conditions.
TTR L55P pre-formed ﬁbrils were incubated with the polyphe-
nols for 4 days at 37 C. At the end of this incubation period, TEM
(Fig. 4A) and DLS (Fig. 4B) analysis evidenced that EGCG, curcumin
and NDGA clearly reduced the amount and size of TTR ﬁbrils
(dH  5000 nm). As expected, EGCG powerfully disrupted TTR
pre-formed ﬁbrils into a polydisperse size particle population of
small amorphous protein aggregates (Fig. 4). Fibril disruption by
curcumin resulted in a major particle population of dH 100 nm
(Fig. 4B), corresponding to small spherical oligomers (Fig. 4A)
while NDGA induced moderate TTR ﬁbril disaggregation as still
larger aggregates and ﬁbrils were occasionally observed in NDGA
treated samples (Fig. 4A).
3.6. Cell toxicity assay
Having characterized the inhibitory properties of EGCG, curcu-
min and NDGA on TTR ﬁbril formation we next evaluated the cyto-
toxicity of the oligomeric species induced by the polyphenols.
Fig. 4. Effect of EGCG, curcumin and NDGA on TTR L55F pre-formed ﬁbrils (t = 0). (A) TTR preparations were incubated in the absence (control) or presence of the different
polyphenols and analyzed by TEM 4 days after incubation. Scale bar = 200 nm. (B) The same samples were analyzed by DLS in the absence (control) and presence of EGCG,
curcumin and NDGA as indicated.
Fig. 3. (A) Immunodetection of TTR aggregates after dot-blot ﬁlter assay of the medium from TTR L55P transfected RN22 cells grown in the absence (control) or in the
presence of EGCG, curcumin and NDGA. (B) Representation of the percentage of aggregation inhibition based on quantiﬁcation of the dots obtained in A (⁄⁄P 6 0.01;
⁄⁄⁄P 6 0.005).
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oligomers alone or pre-treated with polyphenols for 24 h. Cell ly-
sates were used for determination of Caspase-3 activation, and
the results showed that, while extracellular addition of non
-treated TTR oligomers considerably increased intracellular levels
of Caspase-3, EGCG and curcumin induced oligomers signiﬁcantly
alleviate extracellular induced toxicity (77% and 24% reduction,
respectively). NDGA incubated oligomers presented only marginal
reduction (2%) of Caspase-3 activation.4. Discussion
Recent studies on Ab amyloid formation indicate that several
small aromatic compounds interfere with aggregation pathways
possibly by remodeling the amyloid intermediates through differ-
ent mechanisms or interactions [19].
Searching for efﬁcient inhibitors of TTR amyloidosis and consid-
ering that different proteins might share similarities in the misfold-
ing pathway we investigated the effect of natural polyphenols on
TTR amyloid formation and compared to the effect of EGCG. Curcu-
min has been previously reported to bind to TTRWT [20]. However,
no further characterization of the interaction has been conducted.
Herein, we demonstrate that both curcumin and NDGA bind to
TTR WT or TTR V30M in vitro and ex vivo at the T4 binding site.
While NDGA presents the highest T4 displacement potency, curcu-
min revealed to be a stronger tetrameric stabilizer, comparable to
EGCG, indicating that T4 competition potency is not directly related
to TTR stabilization efﬁciency and that curcumin and NDGA may
present different modes of interaction at the T4 binding channel
or may bind to diverse TTR regions. Concerning EGCG, it does not
compete with T4 for the binding to TTR [13] therefore the stabiliza-
tion effect of EGCG on TTR is independent from the stabilization ef-
fect of T4 and additionally strengthens the effect of T4 [21].
Furthermore, the characterization of the EGCG-TTR V30M complex
revealed that EGCG binds at the surface of TTRmolecule, in a region
involving amino acid residues at the interface of both dimmers, pro-
moting tetramer stabilization [21].
The effect of phytochemicals on TTR aggregation inhibition
in vitro was assessed by TEM and DLS analysis using soluble TTR
Y78F that avoids acidiﬁcation to form amyloid in vitro [4]. Curcu-
min presented a potency of aggregation inhibition similar to EGCG
while NDGA presented lower potency. In addition, a detailed anal-
ysis of TTR aggregation dynamics in the presence of each of the
three polyphenols evidenced different modes of action for different
compounds. EGCG treated samples maintained a major particle
population corresponding to soluble TTR while curcumin induced
TTR oligomerization into a monodisperse particle population, cor-
responding to small spherical aggregates. In contrast, NDGA exhib-
ited lesser inhibition potency by presenting larger particles in
solution. We further investigated the polyphenol inhibition prop-
erties on TTR aggregation in cultured cells expressing TTR L55P.
The results obtained corroborated the in vitro studies revealing sig-
niﬁcant TTR aggregation impairment in the cell media by curcumin
(90%) and to a less extent by NDGA (23%).
It is known that early non-ﬁbrillar TTR aggregates are the pri-
mary cytotoxic species,whereas the soluble counterpart andmature
amyloid TTRﬁbrils are not toxic [11,22]. On the other hand, previous
studies have shown that curcumin is able to block Ab 42 and aS oli-
gomer toxicity and increase cell viability in SH-SY5 human neuro-
blastoma cells [14,23]. Likewise, it has been reported that EGCG-
induced Ab 42 and aS oligomers were non-toxic in cell based assays
[24]. In accordance, EGCG and curcumin signiﬁcantly decreased
extracellular TTR oligomeric induced toxicity, indicating that both
produced non-toxic ‘‘off-pathway’’ aggregation species though dif-
ferent size aggregation intermediates were generated in each case.Besides inhibition of aggregation, curcumin and NDGA have
also been reported to destabilize Ab and aS pre-formed ﬁbrils
in vitro and in vivo [15,25]. The results demonstrated that these
phytochemicals disrupted pre-formed amyloid ﬁbrils, though with
different potency. EGCG powerfully disrupted mature TTR ﬁbrils
into a very polydisperse population of protein aggregates support-
ing results obtained for other amyloidogenic variants [13]. Curcu-
min markedly disaggregated amyloid ﬁbrils, originating a
particular population of small amorphous aggregates, morpholog-
ically similar to previously reported curcumin destabilized Ab ﬁ-
brils [15]. NDGA decreased the levels and size of TTR ﬁbrils, but
only to a minor extent.
Several human clinical trials indicate that curcumin is well tol-
erated and non-toxic [26] although a few in vivo studies report ad-
verse effects at very high doses [27]. Therefore, while considering
in vivo testing in mouse model for FAP, different doses of curcumin
or optimized derivatives should be assayed.
In conclusion, the present study demonstrated that curcumin,
NDGA and EGCG, all natural occurring polyphenols, impaired TTR
aggregation through different modes of action: EGCG strongly sup-
pressed TTR tetramer dissociation and mostly sustained TTR as
soluble protein; curcumin induced TTR oligomerization into a char-
acteristic homogeneous population of small ‘‘off-pathway’’ non-
toxic aggregates and NDGA moderately reduced the amount of
TTR aggregation.
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